Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Corcept Therapeutics (CORT)

Corcept Therapeutics (CORT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,577,358
  • Shares Outstanding, K 106,374
  • Annual Sales, $ 761,410 K
  • Annual Income, $ 99,650 K
  • EBIT $ 45 M
  • EBITDA $ 42 M
  • 60-Month Beta 0.29
  • Price/Sales 4.84
  • Price/Cash Flow 38.37
  • Price/Book 5.62

Options Overview Details

View History
  • Implied Volatility 50.62% (-3.29%)
  • Historical Volatility 55.84%
  • IV Percentile 20%
  • IV Rank 13.60%
  • IV High 138.94% on 12/15/25
  • IV Low 36.71% on 08/28/25
  • Expected Move (DTE 23) 3.10 (9.17%)
  • Put/Call Vol Ratio 0.28
  • Today's Volume 252
  • Volume Avg (30-Day) 1,061
  • Put/Call OI Ratio 1.57
  • Today's Open Interest 37,863
  • Open Int (30-Day) 37,504
  • Expected Range 30.72 to 36.92

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.30
  • Number of Estimates 3
  • High Estimate -0.14
  • Low Estimate -0.40
  • Prior Year 0.17
  • Growth Rate Est. (year over year) -276.47%

Price Performance

See More
Period Period Low Period High Performance
1-Month
31.81 +6.32%
on 03/13/26
38.22 -11.50%
on 02/25/26
-2.66 (-7.29%)
since 02/24/26
3-Month
28.66 +18.00%
on 02/19/26
83.70 -59.59%
on 12/26/25
-49.77 (-59.54%)
since 12/24/25
52-Week
28.66 +18.00%
on 02/19/26
117.33 -71.18%
on 03/31/25
-25.65 (-43.13%)
since 03/24/25

Most Recent Stories

More News
Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

BENSALEM, Pa. , March 24, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action...

CORT : 33.82 (+0.56%)
CORT ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent Loss

Lawsuit Alleges Management Concealed Repeated FDA Warnings Regarding Insufficient Data While Touting Pipeline Readiness; Firm Reminds Investors of April 21 Deadline

CORT : 33.82 (+0.56%)
CORT Shareholder Alert: April 21, 2026 Lead Plaintiff Deadline in Corcept Therapeutics Incorporated Securities Class Action Lawsuit -- The Gross Law Firm

NEW YORK , March 24, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Corcept Therapeutics Incorporated (NASDAQ: CORT).

CORT : 33.82 (+0.56%)
Shareholders who lost money in shares of Corcept Therapeutics (NASDAQ: CORT) should contact Wolf Haldenstein immediately

Lead Plaintiff Deadline is April 21, 2026

CORT : 33.82 (+0.56%)
Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

LOS ANGELES , March 23, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ:...

CORT : 33.82 (+0.56%)
Corcept Therapeutics Incorporated Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CORT

LOS ANGELES , March 23, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Corcept Therapeutics Incorporated ("Corcept" or "the Company") (NASDAQ: CORT...

CORT : 33.82 (+0.56%)
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES , March 23, 2026 /PRNewswire/ --  The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Corcept Therapeutics Incorporated...

CORT : 33.82 (+0.56%)
Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks

Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks

CORT : 33.82 (+0.56%)
Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Corcept Therapeutics Incorporated - CORT

NEW ORLEANS , March 20, 2026 /PRNewswire/ -- ClaimsFiler , a FREE shareholder information service, reminds investors that they have until April 21, 2026  to file lead plaintiff applications...

CORT : 33.82 (+0.56%)
CORT INVESTOR ALERT: Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action Following FDA Rejection and Federal Court Patent Loss

Lawsuit Alleges Management Concealed Repeated FDA Warnings Regarding Insufficient Data While Touting Pipeline Readiness; Firm Reminds Investors of April 21 Deadline

CORT : 33.82 (+0.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Corcept is focused on the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncology disorders which are associated with the activity of the hormone cortisol, also known as the stress hormone. Corcept's only marketed drug, Korlym (mifepristone),...

See More

Key Turning Points

3rd Resistance Point 35.40
2nd Resistance Point 34.75
1st Resistance Point 34.29
Last Price 33.82
1st Support Level 33.18
2nd Support Level 32.53
3rd Support Level 32.07

See More

52-Week High 117.33
Fibonacci 61.8% 83.46
Fibonacci 50% 73.00
Fibonacci 38.2% 62.53
Last Price 33.82
52-Week Low 28.66

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.